Disclosures: Simone Fonte: Nothing to Disclose, Marie Laure Plissonnier: Nothing to Disclose, Maud Michelet: Nothing to Disclose, Matthieu Blanchet: Nothing to Disclose, Patrick Labont: Nothing to Disclose, Andrew Vaillant: Replicor Inc.: Employee, Replicor Inc.: Stock privately held company, Massimo Levrero: CLS Behring: Speaking and Teaching, Roche: Grant/Research Support, Ipsen: Grant/Research Support, Gilead: Speaking and Teaching, Gilead: Travel grant, Abbvie: Travel Grant, Inventiva: Travel grant, MSD: Travel grant 416 SAFETY PROFILE OF TOBEVIBART (VIR-3434) AND ELEBSIRAN (VIR-2218) FOR THE TREATMENT OF CHRONIC HEPATITIS B AND DELTA (CHB AND CHD) Alina Jucov 1 Edward Gane 2 Man-Fung Yuen 3 Kosh Agarwal 4 Anca Streinu-Cercel 5 Young-Suk Lim 6 Keith Boundy 7 Cara Pilowa 7 Michael Chattergoon 7 Andre Arizpe 7 Vaidehi Thanawala 7 Shuli Yu 7 Pan Wu 7 Yimeng Lu 7 Todd Correll 7 Tarik Asselah 8 , 1 ARENSIA Exploratory Medicine GmbH, 2 Auckland Clinical Studies, 3 The University of Hong Kong, 4 King's College Hospital, 5 National Institute for Infectious Diseases, 6 Asan Medical Center, 7 Vir Biotechnology, Inc., 8 Hpital Beaujon Background: Tobevibart (VIR-3434) is an investigational fragment crystallizable (Fc)-engineered human monoclonal antibody that binds to the antigenic loop present in all forms of hepatitis B surface antigen (HBsAg)
Pathophysiology of oxidative stress in liver Changes in liver function tests The aging liver is associated with changes in normal liver function tests
Standard protocol includes temperature monitoring throughout storage and pH verification (target 6.07.0) before the first injection
These medications should be a jump start toward a healthy lifestyle with diet and exercise, not a substitute, says the lead author, John Gabriel Horneff III, MD, an associate professor of orthopedic surgery at the University of Pennsylvania in Philadelphia
